New Psoriasis Treatments Work
Raptiva, Arthritis Drug Enbrel Effective and Safe
Raptiva: Targeting T Cells continued...
Mark Lebwohl, MD, of Mt. Sinai School of Medicine in New York, and colleagues treated nearly 600 moderate-to-severe psoriasis patients with two different doses of Raptiva. After 12 weeks of treatment:
- 28% of high-dose patients (2 mg/kg body weight injections once a week) had at least 75% improvement.
- 22% of low-dose patients (2 mg/kg body weight injections every other week) had at least 75% improvement.
"Continued [Raptiva] therapy provided continued benefit," Lebwohl and colleagues report. "In addition, extending the [Raptiva] treatment from 12 to 24 weeks resulted in improved responses in many subjects who did not initially have improvement of 75% or more."
Treatments, Not Cures
Both studies -- and earlier reports of Amevive's efficacy -- are good news for psoriasis patients. None of the treatments offers a cure. But they offer significant relief. And they're a sign of more good things to come.
"One thing is certain -- we have not seen the last of biologic therapies for psoriasis," Kupper notes. "This will ultimately be a boon to patients with this chronic, debilitating disease."